Potential role of tissue transglutaminase in glaucoma filtering surgery

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 9, 2006, Pages 3835-3845

  Priglinger, Siegfried G ^a   Alge, Claudia S ^a   Kook, Daniel ^a   Thiel, Martin ^a   Schumann, Ricarda ^a   Eibl, Kirsten ^a   Yu, Alice ^a   Neubauer, Aljoscha S ^a   Kampik, Anselm ^a   Welge Lussen, Ulrich ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 (GAMMA GLUTAMYL)LYSINE; CADAVERINE; FIBRONECTIN; MESSENGER RNA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA2; DIPEPTIDE; EPSILON (GAMMA GLUTAMYL) LYSINE; EPSILON-(GAMMA-GLUTAMYL)-LYSINE; TGFB2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSGLUTAMINASE 1;

ADULT; ARTICLE; BIOTINYLATION; CELL CULTURE; CONJUNCTIVA; CULTURE MEDIUM; ENZYME ACTIVITY; EYEBALL FASCIA; FIBROBLAST; FILTERING OPERATION; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCISION; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REACTION ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTROCHEMICAL MICROSCOPY; TENON CYST; TRABECULECTOMY; TREATMENT FAILURE; WESTERN BLOTTING; AGED; CONNECTIVE TISSUE CELL; CULTURE TECHNIQUE; DRUG EFFECT; ENZYMOLOGY; EXTRACELLULAR MATRIX; GENETICS; METABOLISM; MIDDLE AGED; OPEN ANGLE GLAUCOMA; PHYSIOLOGY; SCAR;

ADULT; AGED; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CICATRIX; CONNECTIVE TISSUE CELLS; DIPEPTIDES; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBRONECTINS; GLAUCOMA, OPEN-ANGLE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRABECULECTOMY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; TRANSGLUTAMINASES;

EID: 33749120962     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0960     Document Type: Article

References (76)

1. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101:795-798.
2. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK. 1983;103:84-88.
3. Jay JL. Rational choice of therapy in primary open angle glaucoma. Eye. 1992;6:243-247.
4. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994;101:1651-1656.
5. Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, Larkin G. Activation and suppression of fibroblast function. Eye. 1994;8:188-195.
6. Occleston NL, Daniels JT, Tarnuzzer RW, et al. Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behavior. Invest Ophthalmol Vis Sci. 1997;38:1998-2007.
7. Bowness JM, Tarr AH, Wong T. Increased transglutaminase activity during skin wound healing in rats. Biochim Biophys Acta. 1988;967:234-240.
8. Dolynchuk KN, Bendor-Samuel R, Bowness JM. Effect of putrescine on tissue transglutaminase activity in wounds: decreased breaking strength and increased matrix fucoprotein solubility. Plast Reconstr Surg. 1994;93:567-573.
9. Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J. 1999;13:1787-1795.
10. Priglinger SG, May CA, Neubauer AS, et al. Tissue transglutaminase as a modifying enzyme of the extracellular matrix in PVR membranes. Invest Ophthalmol Vis Sci. 2003;44:355-364.
11. Welge-Lussen U, May CA, Lutjen-Drecoll E. Induction of tissue transglutaminase in the trabecular meshwork by TGF-beta1 and TGF-beta2. Invest Ophthalmol Vis Sci. 2000;41:2229-2238.
12. Raghunath M, Cankay R, Kubitscheck U, et al. Transglutaminase activity in the eye: cross-linking in epithelia and connective tissue structures. Invest Ophthalmol Vis Sci. 1999;40:2780-2787.
13. Folk JE, Finlayson JS. The ε-(γ-glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem. 1977;31:1-133.
14. Folk JE. Transglutaminases. Annu Rev Biochem. 1980;49:517-531.
15. Fesus L, Thomazy V, Autuori F, Ceru MP, Tarcsa E, Piacentini M. Apoptotic hepatocytes become insoluble in detergents and chaotropic agents as a result of transglutaminase action. FEBS Lett. 1989;245:150-154.
16. Fesus L, Davies PJA, Piacentini M. Apoptosis-molecular mechanisms in programmed cell death. Eur J Cell Biol. 1991;56:170-177.
17. Aeschlimann D, Paulsson M. Cross-linking of laminin-nidogen complexes by tissue transglutaminase: a novel mechanism for basement membrane stabilization. J Biol Chem. 1991;266:15308-15317.
18. Aeschlimann D, Wetterwald A, Fleisch H, Paulsson M. Expression of tissue transglutaminase in skeletal tissues correlates with events of terminal differentiation of chondrocytes. J Cell Biol. 1993;120:1461-1470.
19. Thomazy V, Fesus L. Differential expression of tissue transglutaminase in human cells. Cell Tissue Res. 1989;225:215-224.
20. Cai D, Ben T, De Luca LM. Retinoids induce tissue transglutaminase in NIH-3T3 cells. Biochem Biophys Res Commun. 1991;175:1119-1124.
21. Verderio EA, Johnson T, Griffin M. Tissue transglutaminase in normal and abnormal wound healing: review article. Amino Acids. 2004;26:387-404.
22. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991;5:3071-3077.
23. Bowness JM, Folk JE, Timpl R. Identification of a substrate site for liver transglutaminase on the aminopropeptide of type III collagen. J Biol Chem. 1987;262:1022-1024.
24. Chen W, Fu X, Sun X, Sun T, Zhao Z, Sheng Z. Analysis of differentially expressed genes in keloids and normal skin with cDNA microarray. J Surg. Res. 2003;113:208-216.
25. Zhang LQ, Laato M, Muona P, Kalimo H, Peltonen J. Normal and hypertrophic scars: quantification and localization of messenger RNAs for type I, III and VI collagens. Br J Dermatol. 1994;130:453-459.
26. Skuta GL, Parrish RK 2nd. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32:149-170.
27. Fourman S, Wiley L. Tissue plasminogen activator modifies healing of glaucoma filtering surgery in rabbits. Ophthalmic Surg. 1991;22:718-723.
28. Kottler UB, Junemann AG, Aigner T, Zenkel M, Rummelt C, Schlotzer-Schrehardt U. Comparative effects of TGF-beta 1 and TGF-beta 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon's capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp Eye Res. 2005;80:121-134.
29. Mietz H, Esser JM, Welsandt G, et al. Latanoprost stimulates secretion of matrix metalloproteinases in Tenon fibroblasts both in vitro and in vivo. Invest Ophthalmol Vis Sci. 2003;44:5182-5188.
30. Kawashima Y, Saika S, Yamanaka O, Okada Y, Ohkawa K, Ohnishi Y. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues. Curr Eye Res. 1998;17:445-451.
31. Daniels JT, Cambrey AD, Occleston NL, et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Invest Ophthalmol Vis Sci. 2003;44:1104-1110.
32. Cordeiro MF, Reichel MB, Gay JA, D'Esposita F, Alexander RA, Khaw PT. Transforming growth factor-beta1, -beta2, and -beta3 in vivo: effects on normal and mitomycin C-modulated conjunctival scarring. Invest Ophthalmol Vis Sci. 1999;40:1975-1982.
33. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40:2225-2234.
34. Connor TB, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83:1661-1666.
35. Hales AM, Chamberlain CG, McAvoy JW. Cataract induction in lenses cultured with transforming growth factor-β. Invest Ophthalmol Vis Sci. 1995;36:1709-1713.
36. Denk PO, Hoppe J, Hoppe V, Knorr M. Effect of growth factors on the activation of human Tenon's capsule fibroblasts. Curr Eye Res. 2003;27:35-44.
37. Mietz H, Chevez-Barrios P, Lieberman MW. A mouse model to study the wound healing response following filtration surgery. Graefes Arch Clin Exp Ophthalmol. 1998;236:467-475.
38. Bundesärtzekammer. Richtlinien zum Führen einer Hornhautbank. Dt Δrztebl. 2000;97:B1805-B1807.
39. Jones E, Clarke J, Khaw PT. Recent advances in trabeculectomy technique. Curr Opin Ophthalmol. 2005;16:107-113.
40. Bohnke M. A new system for storing donor corneas. Klin Monatsbl Augenheilkd. 1991;198:135-137.
41. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239:199-207.
42. Priglinger SG, Neubauer AS, May CA, et al. Optical coherence tomography for the detection of laser in situ keratomileusis in donor corneas. Cornea. 2003;22:46-50.
43. Neubauer AS, Priglinger SG, Thiel MJ, et al. Sterile structural imaging of donor cornea by optical coherence tomography. Cornea. 2002;21:490-494.
44. Kornblihtt AR, Vide-Pedersen K, Baralle FE. Isolation and characterisation of cDNA clones for human and bovine fibronectins. Proc Natl Acad Sci USA. 1983;80:3218-3222.
45. Khaw PT, Ward S, Porter A, Grierson I, Hitchings RA, Rice NS. The long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts. Invest Ophthalmol Vis Sci. 1992;33:2043-2052.
46. Eibl KH, Banas B, Kook D, et al. Alkylphosphocholines: a new therapeutic option in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2004;45:2619-2624.
47. Sane DC, Moser TL, Pippen AM, Parker CJ, Achyuthan KE, Greenberg CS. Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun. 1988;157:115-120.
48. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
49. Jones RA, Nicholas B, Mian S, Davies PJA, Griffin M. Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. J Cell Sci. 1997;110:2461-2472.
50. Vollberg TM, George MD, Nervi C, Jetten AM. Regulation of type I and type II transglutaminase in normal human bronchial epithelial and lung carcinoma cells. Am J Respir Cell Mol Biol. 1992;7:10-18.
51. Ikura K, Shinagawa R, Suto N, Sasaki R. Increase caused by interleukin-6 in promoter activity of guinea pig liver transglutaminase gene. Biosci Biotechnol Biochem. 1994;58:1540-1541.
52. Johnson K, Hashimoto S, Lotz M, Pritzker K, Terkeltaub R. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol. 2001;159:149-163.
53. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-beta1, -beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci. 2000;41:756-763.
54. Lutty GA, Merges C, Threlkeld AB, Crone S, McLeod DS. Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroids. Invest Ophthalmol Vis Sci. 1993;34:477-487.
55. Pasquale LR, Dorman-Pease ME, Lutty GA, Quigley HA, Jampel HD. Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci. 1993;34:23-30.
56. Tripathi RC, Chan WF, Li J, Tripathi BJ. Trabecular cells express the TGF-beta 2 gene and secrete the cytokine. Exp Eye Res. 1994;58:523-528.
57. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
58. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res. 1990;9:963-969.
59. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res. 1996;15:605-614.
60. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44:3394-3401.
61. The Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol. 1989;108:625-635.
62. The Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol. 1996;121:349-366.
63. Goldenfeld M, Krupin T, Ruderman JM, et al. 5-Fluorouracil in initial trabeculectomy: a prospective, randomized, multicenter study. Ophthalmology. 1994;101:1024-1029.
64. Rothmann RF, Liebermann JM, Ritch R. Low-dose 5-fluouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term follow-up. Ophthalmology. 2000;107:1184-1190.
65. Lamping KA, Belkin JK. 5-Fluouracil and mitomycin C in pseudophakic patients. Ophthalmology. 1995;102:70-75.
66. Katz GJ, Higginbotham EJ, Lichter PR, et al. Mitomycin C versus 5-fluouracil in high-risk glaucoma nitration surgery: extended follow-up. Ophthalmology. 1995;102:1263-1269.
67. Doyle JW, Sherwood MB, Khaw PT, McGrory S, Smith MF. Intraoperative 5-fluouracil for nitration surgery in the rabbit. Invest Ophthalmol Vis Sci. 1993;34:3313-3319.
68. Khaw PT, Doyle JW, Sherwood MB, Smith MF, McGorray S. Effects of intraoperative 5-fluouracil or mitomycin C on glaucoma filtration surgery in the rabbit. Ophthalmology. 1993;100:367-372.
69. Shin DH, Juzych MS, Khatana AK, Swendris RP, Parrow KA. Needling revision of failed filtering blebs with adjunctive 5-fluouracil. Ophthalmic Surg. 1993;24:242-248.
70. Allen LE, Manuchehri K, Corridan PG. The treatment of encapsulated trabeculectomy blebs in an out-patient setting using a needling technique and subconjunctival 5-fluouracil injection. Eye. 1998;12:119-123.
71. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol. 1992;110:1049-1050.
72. Parrish R, Minckler D. "Late endophthalmitis": filtering surgery time bomb? Ophthalmology. 1996;103:1167-1168.
73. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluouracil. Am J Ophthalmol. 1992;114:544-553.
74. Wang JY, Johnson LR. Role of transglutaminase and protein cross-linking in the repair of mucosal stress erosions. Am J Physiol. 1992;262:818-825.
75. Priglinger SG, Alge CS, Neubauer AS, et al. TGF-beta2-induced cell surface tissue transglutaminase increases adhesion and migration of RPE cells on fibronectin through the gelatin-binding domain. Invest Ophthalmol Vis Sci. 2004;45:955-963.
76. de Macedo P, Marrano C, Keillor JW. Synthesis of dipeptide-bound epoxides and alpha, beta-unsaturated amides as potential irreversible transglutaminase inhibitors. Bioorg Med Chem. 2002;10:355-360.